Healthcare Feb 06, 2022 10:31 AM (GMT+8) · EqualOcean
EUROHEALTH was informed on the 6th that Sanofi had announced its performance in 2021, with a net income of 37.761 billion euros, a year-on-year increase of 7.1%. Among them, the total revenue of pharmaceutical business was 26.970 billion euros, a year-on-year increase of 7.6%; Vaccine business revenue was 6.323 billion euros, a year-on-year increase of 6.8%. In terms of the geographical distribution of revenue, the US market provided Sanofi with the strongest growth power, with a year-on-year increase of 10.3%, followed by the Chinese market. In 2021, Sanofi's revenue in China was 2.72 billion euros, a year-on-year increase of 7.9%, mainly benefiting from the growth of dupixent and the recovery of Plavix from the impact of volume procurement. Dupulizumab is also Sanofi's current revenue trump card. In 2021, its sales revenue increased by 52.7% year-on-year to 5.249 billion euros.

This text is a result of machine translation.